Skip to main content
SymBio Pharmaceuticals Limited logo

SymBio Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 4582 ISIN · JP3383050006 T Manufacturing
Open in API
Filings indexed 87 across all filing types
Latest filing 2024-08-02 Regulatory Filings
Country JP Japan
Listing T 4582

About SymBio Pharmaceuticals Limited

https://www.symbiopharma.com/en/

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's interim report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type like an interim report. H1 20
2024-08-02 Japanese
半期報告書－第20期(2024/01/01－2024/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It contains comprehensive financial statements, management analysis (MDA), and corporate information for the period from January 1, 2024, to June 30, 2024. As it is a formal interim financial report containing substantive financial data and analysis, it is classified as an Interim/Quarterly Report (IR). H1 2024
2024-08-02 Japanese
四半期報告書－第20期第1四半期(2024/01/01－2024/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, including the balance sheet and management analysis for the first quarter of the 20th fiscal year (January 1, 2024, to March 31, 2024). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-08 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is extremely short (632 characters) and contains a header structure typical of Japanese regulatory filings, specifically mentioning a '確認書' (Confirmation Document) submitted to the Kanto Local Finance Bureau Director based on Article 24-4-8, Paragraph 1 of the Financial Instruments and Exchange Act. The content explicitly states that the Representative Director and CFO have confirmed the appropriateness of the '第20期第１四半期(自2024年１月１日 至2024年３月31日)の四半期報告書' (Quarterly Report for the 1st Quarter of the 20th Period). Since this document is a confirmation *about* the Quarterly Report, and not the comprehensive report itself, it falls under the category of a regulatory filing that doesn't fit other specific types, or potentially a specific type of regulatory confirmation. Given the options, it is a specific regulatory document related to financial reporting confirmation. However, since it confirms the content of a Quarterly Report (which would typically be classified as IR), and this confirmation document itself is a specific regulatory submission, it best fits the general 'Regulatory Filings' (RNS) category as a fallback, or potentially an Audit Report/Information (AR) if it were a formal certification, but it seems more like a procedural confirmation. Given the context of confirming a Quarterly Report, and the document being a short confirmation rather than the full report, RNS is the safest general regulatory fallback.
2024-05-08 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document header explicitly states the filing type as "臨時報告書（2024年４月19日付け訂正報告書の添付インラインXBRL）" which translates to 'Extraordinary Report (Inline XBRL attached to the Correction Report dated April 19, 2024)'. The body of the text confirms this is a '訂正報告書' (Correction Report) filed based on Article 24-5, Paragraph 5 of the Financial Instruments and Exchange Act, correcting details from a previously filed '臨時報告書' (Extraordinary Report). In the context of Japanese regulatory filings, an Extraordinary Report (臨時報告書) is generally used for significant, unscheduled events. When a document details the issuance of stock options (新株予約権) to directors and employees, it relates to capital structure changes or financing activities. However, the core nature of this specific document is a *correction* to a prior filing regarding the finalization of stock option issuance details (issuance count, price, total value, etc.). Reviewing the provided definitions: - 10-K/IR: Not an annual or interim comprehensive report. - ER: Not a standard earnings release. - CAP (Capital/Financing Update): While stock options are related to capital, this document is a *correction* filing. - RNS (Regulatory Filings): This is the most appropriate general category for specific, non-standard regulatory filings like a correction report (訂正報告書) that doesn't fit the highly specific categories like DIV, SHA, or POS, especially when the original filing was an Extraordinary Report (which often defaults to RNS if not otherwise specified). Given the document is a formal correction to a prior filing concerning the issuance of stock options (a significant corporate action), and it is structured as a formal Japanese regulatory submission (様式第五号の三), classifying it under the general regulatory fallback category 'RNS' (Regulatory Filings) is the most accurate choice among the provided options for a correction report that isn't a standard periodic report or a simple announcement of a report's publication.
2024-04-19 Japanese
臨時報告書
Regulatory Filings
2024-03-25 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.